These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6661515)

  • 1. The pharmacokinetics of HI-6 in beagle dogs.
    Simons KJ; Briggs CJ
    Biopharm Drug Dispos; 1983; 4(4):375-88. PubMed ID: 6661515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition of HI-6 oxime in rats after intravenous and intramuscular administration.
    Simons KJ; Briggs CJ
    J Pharm Pharmacol; 1985 May; 37(5):367-9. PubMed ID: 2862253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability and disposition kinetics of HI-6 in Beagle dogs.
    Baggot JD; Buckpitt A; Johnson D; Brennan P; Chung H
    Biopharm Drug Dispos; 1993 Mar; 14(2):93-105. PubMed ID: 8453028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HI-6 pharmacokinetics in rabbits after intravenous and intramuscular administration.
    Lukey BJ; Woodard CL; Clark CR; McCluskey MP
    J Pharm Pharmacol; 1992 Aug; 44(8):690-2. PubMed ID: 1359099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of atropine in dogs after i.m. injection with newly developed dry/wet combination autoinjectors containing HI 6 or HLö 7.
    Thiermann H; Radtke M; Spöhrer U; Klimmek R; Eyer P
    Arch Toxicol; 1996; 70(5):293-9. PubMed ID: 8852700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous application of HI-6 salts (dichloride and dimethansulphonate) in pigs: comparison with pharmacokinetics profile after intramuscular administration.
    Zdarova Karasova J; Zemek F; Kunes M; Kvetina J; Chladek J; Jun D; Bures J; Tachecí I; Kuca K
    Neuro Endocrinol Lett; 2013; 34 Suppl 2():74-8. PubMed ID: 24362096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of the oximes HI 6 and HLö 7 in dogs after i.m. injection with newly developed dry/wet autoinjectors.
    Spöhrer U; Thiermann H; Klimmek R; Eyer P
    Arch Toxicol; 1994; 68(8):480-9. PubMed ID: 7802588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disposition of antimony after the administration of N-methylglucamine antimoniate to dogs.
    Valladares JE; Alberola J; Esteban M; Arboix M
    Vet Rec; 1996 Feb; 138(8):181-3. PubMed ID: 8677619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic study of cefmenoxime (SCE 1365-CMX) in healthy adults.
    Fourtillan JB; Bryskier A; Mignot A; Borsa F; Humbert G
    Am J Med; 1984 Dec; 77(6A):28-31. PubMed ID: 6097120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trimedoxime and HI-6: kinetic comparison after intravenous administration to mice.
    Milic B; Maksimovic M; Nedelijkovic M
    Pharmacol Toxicol; 1996 Apr; 78(4):269-72. PubMed ID: 8861786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The acetylcholinesterase oxime reactivator HI-6 in man: pharmacokinetics and tolerability in combination with atropine.
    Clement JG; Bailey DG; Madill HD; Tran LT; Spence JD
    Biopharm Drug Dispos; 1995 Jul; 16(5):415-25. PubMed ID: 8527690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and toxicity of the oxime HGG 12 in dogs.
    Klimmek R; Eyer P
    Arch Toxicol; 1985 Sep; 57(4):237-42. PubMed ID: 4091648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HI-6 in man: blood levels, urinary excretion, and tolerance after intramuscular administration of the oxime to healthy volunteers.
    Kusić R; Bosković B; Vojvodić V; Jovanović D
    Fundam Appl Toxicol; 1985 Dec; 5(6 Pt 2):S89-97. PubMed ID: 4092899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetics, distribution, and biotransformation of the chemical HI-6 in the rat, dog, and rhesus monkey.
    Ecobichon DJ; Comeau AM; O'Neil WM; Marshall WD
    Can J Physiol Pharmacol; 1990 May; 68(5):614-21. PubMed ID: 2340450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefotaxime in the dog.
    Guerrini VH; English PB; Filippich LJ; Schneider J; Bourne DW
    Vet Rec; 1986 Jul; 119(4):81-3. PubMed ID: 3750783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral kinetics and bioavailability of the cholinesterase reactivator HI-6 after administration of 2 different formulations of tablets to dogs.
    Maksimović M; Jovanović D; Kovacević V; Bokonjić D
    Toxicol Lett; 1987 Nov; 39(1):85-91. PubMed ID: 3672559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma pharmacokinetics and bioavailability of 1-(2-chloroethyl)-3-sarcosinamide-1-nitrosourea after intravenous and oral administration to mice and dogs.
    Supko JG; Garcia-Carbonero R; Puchalski TA; Malspeis L
    Cancer Chemother Pharmacol; 2001 Sep; 48(3):202-8. PubMed ID: 11592341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of single doses of cefoperazone given by the intravenous and intramuscular routes to unweaned calves.
    Soback S; Ziv G
    Res Vet Sci; 1989 Sep; 47(2):158-63. PubMed ID: 2799072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formation of cyanide after i.v. administration of the oxime HI 6 to dogs.
    Eyer P; Kawan A; Ladstetter B
    Arch Toxicol; 1987; 61(1):63-9. PubMed ID: 3439876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of N-methylglucamine antimoniate after intravenous, intramuscular and subcutaneous administration in the dog.
    Tassi P; Ormas P; Madonna M; Carli S; Belloli C; De Natale G; Ceci L; Marcotrigiano GO
    Res Vet Sci; 1994 Mar; 56(2):144-50. PubMed ID: 8191002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.